A major unanswered question of glucocorticoid and progesterone action is how different whole cell responses arise when both of the cognate receptors can bind to, and activate, the same hormone response elements (HREs). We have previously documented that the EC 50 of agonist complexes, and the partial agonist activity of antagonist complexes, of both glucocorticoid receptors (GRs) and progesterone receptors (PRs) are modulated by increased amounts of homologous receptor and of coregulators. We now ask whether these components can differentially alter GR and PR transcriptional properties. To remove possible cell-specific differences, we have examined both receptors in the common environment of a line of mouse mammary adenocarcinoma (1470.2) cells. In order to segregate the responses that might be due to unequal nucleosome reorganization by the two receptors from those reflecting interactions with other components, we chose a transiently transfected reporter containing a simple glucocorticoid response element, or GRE (i.e., GREtkLUC). No significant differences are found with elevated levels of either receptor. However, major, qualitative differences are seen with the corepressors SMRT and NCoR, which afford opposite responses with GR and PR. Studies with chimeric GR/PR receptors indicate that no one segment of PR or GR is responsible for these properties and that the composite response likely involves interactions with both the N-and C-termini of receptors. Collectively, the data suggest that GR and PR induction of responsive genes in a given cell can be differentially controlled, in part, by unequal interactions of multiple receptor domains with assorted nuclear cofactors.
Introduction
Among the longstanding conundrums of steroid hormone action is why different whole cell responses are observed for androgen, glucocorticoid, mineralocorticoid, and progestin steroid hormones (1) even though each receptor-steroid complex can bind to the same DNA sequences to induce gene transcription (2, 3) . Steroid hormone regulated gene transactivation requires ligand binding to the cognate intracellular receptor. After binding to biologically active DNA sequences, called hormone response elements (HREs), the activated complexes are thought to recruit transcriptional coregulators and components of the transcriptional complex prior to modifying the transcription rates of target genes.
Different ligands bind to the various steroid receptors with different affinities. However, this specificity for the different steroid hormones would seem to soon disappear as the activated form of each complex of the above four steroid receptors can bind to, and activate transcription from, the same HREs.
The actions of glucocorticoid receptors (GRs) and progesterone receptors (PRs) have been extensively studied in an effort to understand how biological diversity can be maintained when the activated receptor complexes act on a common HRE. Several explanations have been proposed, including different levels of the receptor within a given cell (4) . HRE mutations have also been reported to differentially affect GR vs. PR transactivation (5) , although the differences seem to be less pronounced when receptor concentrations are about equal (6) . Nelson et al. found that the flanking and spacer DNA of the palindromic HRE can contribute to the affinity and specificity of receptor binding (7) . Page 5 complexes, especially in cell-free systems (13, 14) . Chromatin environment can control gene inducibility by PR (15) (16) (17) and chromatin structure has been proposed to be a determinant for PR induction (10, 15) . However, alterations in chromatin structure do not appear to be a prerequisite for all steroid receptor-induced gene transactivation. In several cases, chromatin reorganization appears to precede the actions of receptor-steroid complexes in inducing gene expression (14, (18) (19) (20) while in other cases, chromatin disruption or remodeling is not sufficient for transactivation, which requires a second step (21) . In T47D cells lacking both PR and GR, or expressing only GR, the responsive B nucleosome of the MMTV enhancer is in a constitutively "open" state, indicating that GR transcriptional activation is independent of chromatin remodeling (20) .
The low homology of the amino terminal halves of GR and PR (<15%) has been advanced as an additional possible cause for selective gene expression (22) . One mechanism by which this could be achieved is through differential interactions with the recently discovered transcriptional coregulators such as coactivators and corepressors.
While the initially determined interactions of these coregulators were with the ligand binding domain (LBD) of receptors (23) (24) (25) , several recent reports describe interactions with the amino terminal domain of receptors (26) (27) (28) (29) (30) (31) . Unfortunately, receptor-specific interactions with coregulators appear limited. ARA70 (((32) vs. (33, 34) ) and FHL2 (35) have been described to be specific coactivators for ARs while a 68K protein (p68) appears to be a coactivator for estrogen receptor (ER) α but not for ERβ, AR, mineralocorticoid receptors, or retinoic acid receptor α (36) . REA selectively interacts with estrogen receptors to decrease both the activity of agonists and the concentration of antiestrogens required for half-maximal inhibition of estrogens (37) . NRIF3 is a ligand-dependent specific coactivator that binds (and augments transactivation of) TR and RXR but not RAR or VDR or steroid receptors (38) .
More evidence exists for differential effects of coactivators and corepressors on GR vs. PR activities. The nuclear orphan receptor ERRS is described to be a repressor of GR transcriptional activity but does not affect PR activity (39) . Conversely, PIAS1 enhances GR transactivation but represses PR transactivation in the same system (40) . A 130K auxiliary protein increases the DNA binding of full length GR but not truncated PRs (41) . Similar quantitative differences have been noted for other steroid receptors. SRC-1 has a greater effect on ER than AR action in the brain of developing rats (42) , which may result from SRC-1 interacting with the ER LBD via the LxxLL motifs of SRC-1 but with the amino terminal region of AR in a manner that does not depend on the SRC-1 LxxLL motifs (34) .
SRC-1e interacts with the fragments containing the DNA binding domain and LBD of ER but not of AR (28) . RIP140 represses GR (43) but increases AR (44) transactivation.
Whether Zac1 augments or represses the activity of GRIP1 with AR vs. ER depends on the target gene and cell (45) .
Recently we have found that varying concentrations of the homologous receptor, coactivators, and corepressors can alter the EC 50 of agonist complexes, and the partial agonist activity of antagonist complexes, for both GRs (46) (47) (48) and PRs (49) . Preliminary evidence suggested that the responses of GR and PR to these factors might be different (47) (48) (49) . The purpose of this study was, therefore, to examine whether the quantitative activities of those factors known to alter PR and GR transactivation properties are the same or different for PR and GR. To answer this question, we have performed multiple doseresponse curves to determine the EC 50 of agonists and the partial agonist activity of antagonists. It was important to conduct these assays in the same cells so that cell-specific contributions to transcriptional activities could be eliminated. Similarly, we needed to use the same reporter so that effects of chromatin organization would be minimized. In the context of such an assay system, we found two instances in which the induction properties of PR and GR were qualitatively different, with almost opposite effects being produced by the same added component. Further studies with PR/GR chimeras indicated that no one segment of PR or GR was responsible for these differences. Collectively, the data suggest that the differences between GR and PR induction in a selected cell can be controlled, in part, by unequal responses from the combination of amino-and carboxyl-terminal domains of each receptor to assorted nuclear components.
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Life Technologies, Inc., and DMEM with 4.5g glucose/L, Quality Biologicals, Inc., respectively) supplemented with 5% and 10% of fetal bovine serum (FBS), respectively.
We had previously used charcoal-stripped serum with 1470.2 cells to prevent any PRmediated induction by endogenous progestins (49) . However, we have confirmed the observations of others (55) that this is not necessary (data not shown). Therefore, charcoal-stripped serum was no longer used with 1470.2 cells. CV-1 cells were grown as described (46) . Coregulator plasmids were transiently co-transfected into 1470.2 cells using Lipofectamine (LIfe Technologies, Inc.) with hPR-B receptor-containing plasmid, 1µg
of GREtkLUC, and 50ng Renilla null luciferase, with the total transfected DNA brought up to 3 µg/60 mm dish with pBSK + DNA (56) . In experiments with varying amounts of receptor or coregulator cDNA plasmids, equimolar amounts of the same plasmid vector were cotransfected to control for artifacts of the vector DNA. The cells were treated for 24 hr with 1% ethanol ± steroids in media containing 10% FBS and harvested in 1x Passive Lysis Buffer (0.5 ml / dish, Promega). Fifty µl of the cell lysates were used to assay for luciferase activity using the Dual-Luciferase Assay System from Promega (Madison, WI) according to the supplier. The data were then normalized for the cotransfected Renilla activity.
Steroid Binding Assays. Transient transfection of COS-7 cells with 1 µg/10 cm plate of GR or PR/GR plasmid DNA and 19 µg of single stranded DNA was performed as described (57) . Cytosols of transfected cells containing the steroid-free receptors were obtained by the lysis of cells on dry ice and centrifugation at 15,000 xg (58 The dose-response curves were constructed from the theoretical sigmoidal curve for the binding isotherm, which is described by the equation of y = x/(x+k), where y = the fractional response, x = the concentration of free steroid, and k = an arbitrary value for the binding affinity of steroid to receptor. This theoretical curve was then aligned with the experimental data so as to give the best visual fit.
Unless otherwise noted, all statistical analyses were by two-tailed Student's t test using the program "InStat 2.03" for Macintosh (GraphPad Software, San Diego, CA). and Oct1 to the MMTV promoter (62) . In order to avoid these additional complications, we elected to use the simpler GREtkLUC reporter, which does not contain cis-acting binding sequences for other transcription factors. We first determined that higher concentrations of hPR-B plasmid afford increased total reporter activity, indicating that PR is limiting in this range (Fig. 1A) . Under these conditions, the dose-response curve (or EC 50 ) for R5020 induction of the transiently transfected GREtkLUC reporter is shifted to lower steroid concentrations and the partial agonist activity of the antiprogestin dexamethasone mesylate (Dex-Mes) (49) is increased (Fig. 1B) . Thus, we see the same responses to changing PR concentrations with the GREtkLUC reporter as for the MMTVLUC reporter (49). We Page 11
Results

Selection of assay system:
conclude that the ability of added PR to reposition the dose-response curve is independent of the GRE and promoter sequences.
It should be noted that the endogenous GR of 1470.2 cells does not interfere with the quantitation of PR induction. Not only does Dex display negligible activity with PR but also Dex-Mes and R5020 have little or no activity with the endogenous GR (49).
We previously reported that increasing amounts of transiently transfected GR produce a left-shift for the induction of a GREtkLUC reporter in HeLa and CV-1 cells (46) . However, no further left-shift (or increased partial agonist activity of antiglucocorticoids) is seen with high concentrations of GR (>1 µg of plasmid), indicating that there is a limit to the effects of added GR (48) . 1470.2 cells contain some GR (49) . Under conditions where added GR increases the total transactivation of cotransfected GREtkLUC in 1470.2 cells, the higher levels of GR also afford about a two-fold left-shift in the dose-response curve with dexamethasone (Dex) (Fig. 1C) . At the same time, the very low amount of partial agonist activity of Dex-Mes and dexamethasone oxetanone (Dex-Ox) with GR in 1470.2 cells (49) increases ( These data indicate that the transactivation properties of GR and PR are similarly altered by elevated levels of receptor.
Modulation of PR and GR activities by NCoR:
We recently observed that added corepressor NCoR (63) had no effect on GR transactivation of GREtkLUC in CV-1 cells With the endogenous GR of 1470.2 cells, added NCoR also reduced the total transactivation by 27 ± 11% (S.E.M., n = 4) and increased the fold induction (54 ± 18%, S.E.M., n = 4), just as was observed above for PR. However, the effect on the other GR transactivation properties was almost exactly the reverse as seen with PR (Fig. 2B) . NCoR afforded an average of a 2.1 ± 0.2 fold (S.E.M., n = 4, P = 0.011) right-shift in the doseresponse curve. The slight decrease in the low partial agonist activity of Dex-Ox was not statistically significant (to 84 ± 31%, n=3, P = 0.47).
Modulation of PR and GR activities by SMRT:
The transfection of SMRT cDNA causes a right-shift in the dose-response curve, and decreases the partial agonist activity of antisteroids, both for GR induction of GREtkLUC in CV-1 cells (47) and for PR induction of MMTVLuc in 1407.2 cells (49) . When PR induction properties were determined with a different reporter, GREtkLUC, SMRT still affords a right-shift (3.2 ± 0.6 fold, n = 2) in the EC 50 and a 54 ± 1% (n = 2) decrease in the partial agonist activity of Dex-Mes (Fig. 3A) .
Interestingly, when GR induction was examined, the addition of SMRT no longer yields a right-shift. Instead, a weak left-shift (1.4 ± 0.2 fold, S.E.M., n = 5) is obtained (Fig. 3B) while causing a 33 ± 10% (S.E.M., n = 5, P = 0.032) decrease in the total transactivation.
The magnitude of the left-shift of the GR dose-response curve with SMRT is not statistically significant (P = 0.11). However, the observation that SMRT causes a right-shift with PR and little or no left-shift with GR is significant (P = 0.025). At the same time, the low partial agonist activity of Dex-Ox (8.0 ± 0.7%, S.E.M., n = 5) is increased by SMRT to 9.9 ± 0.6% (S.E.M., n = 5, P = 0.048 in paired Student t Test). This result further supports a left shift in the GR dose-response curve by SMRT because a shift in the dose-response curve to the left has always been accompanied by increased partial agonist activity of an antisteroid 
Responses of chimeric GR/PR receptors:
In an effort to understand the origins of the divergent responses of GR and PR transactivation properties to NCoR and SMRT, we asked whether the individual biological effects require specific domains of each receptor.
For this, we selected chimeras in which the amino terminal and DBD domains of one receptor were fused to the LBD of the other to give the hybrid receptors that we call PR/GR and GR/PR (Fig. 4A) . In both cases, the junction is seamless so that no mutations have been introduced in the body of the receptors. The construction of the chimeras did result in changes at the amino termini (see Fig 6A) . However, these changes have not been not shown). To be sure that these properties are not influenced by the endogenous GR of 1470.2 cells, the PR/GR chimera was further examined in CV-1 cells, which contain much lower levels of functional GR (46) (47) (48) . Here, the same two concentrations of PR/GR cause a 7.13 ± 0.07 (S.E.M., n = 3, P = 0.0001) fold left-shift in the dose-response curve and a 31 ± 7% (S.E.M., n = 3, P < 0.050) increase in the partial agonist activity of Dex-Mes (Fig. 4C) .
Interestingly, under conditions where the total transactivation of GREtkLUC by 30 ng of PR/GR and 100 ng of GR is the same (consistent with equivalent amounts of transcriptionally active GR and PR/GR complexes), the dose-response curves and partial agonist activities with the two receptors are dramatically different (see also below).
Added SMRT plasmid causes a slight left-shift with GR and a right-shift with PR (Fig. 3 ).
With the chimeric receptors, SMRT produces a weak right-shift with PR/GR and a stronger right-shift with GR/PR ( Fig. 5A and B) . The receptors can thus be ordered by decreasing ability of SMRT to afford a left-shift as follows, with the value for the fold left-shift in parentheses: GR (1.41 ± 0.2) > PR/GR (0.79 ± 0.11) > GR/PR (0.46 ± 0.09) > PR (0.33 ± 0.06) (± S.E.M. with n = 5 for all samples except PR, where ± range, n = 2). These differences are significant with P = 0.027 for GR vs. PR/GR, P = 0.049 for PR/GR vs.
GR/PR, and P = 0.0027 for GR vs. GR/PR. This ordering is maintained when the effect of SMRT on the partial agonist activity of the various antisteroids is expressed in terms of increased agonist activity, with 100% being the control value: GR (127 ± 10%) > PR/GR (75 ± 3%) > GR/PR (58 ± 8%) > PR (46 ± 1%) (P = 0.009 for GR vs. PR/GR and 0.08 for PR/GR vs. GR/PR, both using Welch's t Test) (see Figs. 3 and 5A&B). We therefore conclude that not only can the action of SMRT differ among receptors but also the eventual response results from a combination of the amino and carboxyl terminal regions of PR and GR as opposed to the actions of any one domain.
Similar conclusions were obtained from experiments on NCoR action with the chimeric receptors. NCoR shifted the dose-response curve of PR/GR to the left by a factor of 1.52 ± 0.14 (S.E.M., n=3) ( Fig. 5C ) but had no significant effect on GR/PR (Fig. 5D) . The rank order of altered dose-response curve by NCoR, with the fold left-shift in parentheses, was 
Comparison of the PR/GR chimera with wild type GR:
We noted above (Fig. 4C ) that the dose-response curve for PR/GR is considerably left-shifted from that for GR. This was unexpected because steroid binding to the receptor is thought to be the determining factor for the dose-response curve and both GR and PR/GR contain the same LBD (67). This This suggests that the differences in transactivation properties of GR vs. PR/GR are not limited by the concentration of expressed receptors but rather reflect intrinsic transactivation properties of the wild type GR and the PR/GR chimeric receptors.
One trivial explanation for the different properties of PR/GR vs. GR is that the presence of the PR amino terminal domain and/or DBD somehow increases the affinity of Dex for the GR LBD. This explanation can be eliminated, though, because the cell-free affinity of Dex is the same for both receptors in a cell-free Scatchard assay (Fig. 6C) . Similarly, whole cell binding assays at 37°C reveal that there is no appreciable difference in Dex binding to PR/GR and GR under the conditions of the whole cell bioassay (Fig. 6D) . Therefore, the lower EC 50 of PR/GR, compared to GR, is not the result of any difference in affinity between the receptors for ligand at either 0 or 37°C.
Discussion
This study presents evidence that changes in the concentration of the corepressors NCoR and SMRT can modify selected transcriptional properties of GR differently than those of PR. The most commonly examined transcriptional properties of steroid receptors are the total transactivation and the fold induction. None of the species in this study influence these properties of GR appreciably more or less than those for PR. However, notable differences can be seen between GR and PR with regard to changes in the doseresponse-curve, or EC 50 , and the partial agonist activity of antisteroids. These two properties of receptor-steroid complexes have important physiological and pathological consequences. Physiological levels of steroids are rarely sufficient for maximal induction and commonly correspond to the concentrations required for half-maximal induction, or the EC 50 . Therefore, changes in EC 50 of a gene will result in significant differences in the expressed activity under physiological conditions. We do not know how similar the magnitude of responses in intact animals will be to our results in transfected cells. However, the effects could even be greater. In transgenic mice with about a 50% higher level of GR protein, due to a 100% increase in the GR gene dosage, the dose-response curve for glucocorticoid induced, DNA-binding dependent apoptosis of primary thymocytes (68) is left-shifted to lower steroid concentrations by a factor of greater than 10 (69).
Conversely, in cells from transgenic flies carrying the human estrogen receptor and an estrogen receptor responsive reporter and no known coactivators, the EC 50 for reporter induction by estradiol was right shifted by a factor of about 100 (70) . The other transactivation parameter that we investigated, i.e., changes in the partial agonist activity of antisteroids, is highly relevant for endocrine therapies. An antisteroid that displays high levels of partial agonist activity for the very gene that one wishes to suppress would clearly be contraindicated. Alternatively, increased levels of partial agonist activity, which is characteristic of selective receptor modulators (SRMs), is often desirable. To the extent that side effects of antisteroid therapies result from the suppression of all responsive genes, an antisteroid with partial agonist activity for as many genes as possible, other than the one to be repressed, would be extremely useful.
In this study, we find that the corepressors NCoR and SMRT affect both the EC 50 (Fig. 3A) and MMTV (49) reporter.
Unexpectedly, the response of GR to added SMRT for induction of GREtkLUC in 1470.2 cells is the opposite of PR. The GR dose-response curve is repositioned to lower EC 50 s and the partial agonist activity of antisteroids increases (Fig. 3B ). This argues not only that the responses of a given receptor can vary among cell types (i.e., GR in CV-1 vs. 1470.2 cells) but also that the same cofactor can produce diametrically opposite effects for the transactivation properties of two different steroid receptors (GR and PR) acting on the same gene in the same cell. Similarly, the effects of NCoR with GR and PR are cell-and receptor-selective. The response of PR to added NCoR is the same for GREtkLUC ( Fig.   2A ) and MMTVLuc (49) and thus is independent of the reporter. In contrast, NCoR modulates GR the transactivation properties for GREtkLUC induction in 1470.2 cells (Fig.   2B ) but not in CV-1 cells (47) . Furthermore, NCoR shifts the dose-response curves for GR and PR induction of GREtkLUC in 1470.2 cells in opposite directions and has opposite effects on the partial agonist activity of antisteroids (Fig. 2) . Earlier studies have also documented specificity in receptor binding of coactivators and corepressors (71, 72) . appear to be common among the steroid/nuclear receptors and have been observed for GR (73) , PR (74) , androgen receptors (44, 75) estrogen receptors (76) , and PPAR receptors (77) . Similarly, we propose that the combination of N-and C-terminal sequences forms a surface that differentially interacts with cell-specific factors, thereby giving rise to the unequal transcriptional responses regarding the EC 50 and partial agonist activity (Fig.   7) . These cell-specific factors would be expected to include the corepressors, given the above consequences of added NCoR and SMRT. We do not yet have any evidence for the corepressors directly contacting GR. Initially, it was thought that NCoR and SMRT bound only to the nuclear receptors. More recently, however, NCoR and SMRT have been shown to bind to antagonist complexes of PR and ER (26, (78) (79) (80) and the amino terminal domain of receptors may be involved (31) in addition to the LBD (81) (82) (83) . Significantly, others (78, 79) , in addition to ourselves (47, 49) , have reported effects of corepressors on the total transactivation of agonist-bound ER, PR, and GR complexes. These data support an interaction of corepressors with agonist-, as well as antagonist-, bound receptors. Further support for the importance of N-and C-terminal sequence interactions in determining the transactivation properties of GR and PR comes from the PR/GR chimera. While the steroid binding affinity of PR/GR at 0 and 37°C is, as expected, the same as that of wild type GR (Fig. 6) , the EC 50 for Dex induction of GREtkLUC, and the partial agonist activities of antisteroids, are quite different (Fig. 4C) . The simplest explanation is that the combination of domains alters steps in transactivation that follow steroid binding to the receptor in a way that increases the sensitivity to circulating steroids, as outlined in Fig. 7 .
A differential effect of cofactors on steroid receptor regulated-gene transcription is an attractive mechanism for conveying unequal transactivation properties to receptors that bind to common DNA targets. As is described in the present study with GR and PR, this 
